Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bedaquiline

- PMLiVE

FDA approves UCB’s Rystiggo to treat generalised myasthenia gravis

The rare autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections

AMR has been declared by WHO as one of the top ten threats to global health

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

- PMLiVE

FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis

Ayvakit is now the first and only approved medicine designed to treat the underlying cause of the disease

- PMLiVE

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

The candidates have shown the potential to treat forms of non-Hodgkin’s lymphoma

- PMLiVE

Janssen’s Akeega receives EC approval for metastatic prostate cancer

The authorisation marks the first worldwide approval of the niraparib-based combination

- PMLiVE

Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

- PMLiVE

Johnson & Johnson offers $8.9bn to resolve all talcum powder lawsuits

The company faces more than 38,000 lawsuits alleging that its talc products cause cancer

- PMLiVE

Johnson & Johnson’s strategy to resolve talcum powder lawsuits blocked by US appeals court

The company faces more than 38,000 lawsuits alleging that its talc products contain asbestos

- PMLiVE

NHS England announces rare genetic disorder fast-tracking service

Patients with inherited white matter disorders will benefit from earlier diagnosis and specialist care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links